Results 121 to 130 of about 20,950 (257)

Interleukin-17 as a Therapeutic Target in Psoriasis [PDF]

, 2014
A psoríase é uma doença crónica, inflamatória, imunomediada que afecta cerca de 1-3% da população geral. O avanço no conhecimento da patogénese da psoríase levou ao desenvolvimento de novos fármacos direccionados para vias imunitárias mais específicas ...
Filipe, P., Torres, T.
core  

Emerging Therapies for the Treatment of Psoriasis [PDF]

, 2012
Psoriasis is an immune-mediated disease that affects 1%–2% of the European and North American population. While topical agents such as corticosteroids and vitamin D derivatives are prescribed for mild disease, they are generally unable to adequately ...
Alan Menter, Antoinette Day, Mahir Patel, Richard B. Warren   +3 more
core   +1 more source

Comparative Efficacy and Safety of Ustekinumab and Secukinumab in the Treatment of Generalized Pustular Psoriasis: A 48-Week Retrospective Cohort Study with Genetic Background Analysis

Journal of Inflammation Research
Purpose Recent studies have shown that novel biologics may provide significant clinical benefits for patients with generalized pustular psoriasis (GPP). Ustekinumab and secukinumab have been approved in Japan for GPP treatment in adult patients. However,
Shi-Fan Ruan, Xinhong Su, Zhixun Xiao, Yihua Zhang, Tingting Lin, Renwei Luo, Niu Xiang, Bo Cheng, T. Gong, Chao Ji   +9 more
semanticscholar   +1 more source

Biologic treatments for psoriasis have different anatomical specificities in residual PASI

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Improved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI ...
Martina Burlando, Irene Schiavetti, Aurora Parodi, Emanuele Cozzani, Luca Mastorino, Eleonora Bongiovanni, Ilaria Salvi, Martina Del Vecchio, Paolo Dapavo   +8 more
wiley   +1 more source

Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

Reumatismo
Objective. Drug survival rate and time are important to demonstrate the effectiveness of treatment in patients with axial spondyloarthritis (axSpA) in real life.
Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Bahar Özdemir Ulusoy, Özlem Karakaş, Kevser Orhan, Rezan Koçak Ulucaköy, Esra Kayacan Erdoğan, Serdar Can Güven, Orhan Küçükşahin, İsmail Doğan, Hakan Babaoğlu, Yüksel Maraş, Şükran Erten, Ahmet Omma, Berkan Armağan   +15 more
doaj   +1 more source

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

RMD Open
Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.
S. N. Christiansen, S. Horskjær Rasmussen, Mikkel Ostergaard, Marion Pons, B. Michelsen, K. Pavelka, C. Codreanu, A. Ciurea, B. Glintborg, M. J. Santos, Ismail Sari, Ž. Rotar, B. Gudbjornsson, G. J. Macfarlane, H. Relas, F. Iannone, K. Laas, J. Wallman, M. V. D. van de Sande, S. Provan, Isabel Castrejón, Jakub Závada, C. Mogosan, Michael J Nissen, A. G. Loft, A. Barcelos, Y. Erez, K. Pirkmajer, G. Grondal, Gareth T. Jones, A. Hokkanen, M. Chimenti, S. Vorobjov, D. di Giuseppe, Tore K. Kvien, L. Otero-Varela, Irene E van der Horst-Bruinsma, M. Hetland, L. Ørnbjerg   +38 more
semanticscholar   +1 more source

S1‐Guideline for diagnosis and therapy of necrobiosis lipoidica

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Necrobiosis lipoidica (NL) is a rare granulomatous skin disease of unknown etiology that occurs frequently in association with diabetes mellitus and other comorbidities. The predilection site is the lower leg, particularly the pretibial areas. The exact pathogenesis remains unclear.
Cornelia Erfurt‐Berge, Regina Renner, Melanie Peckruhn, Jörg Tittelbach, Dorothea Terhorst‐Molawi, Friederike Kauer, Joachim Dissemond   +6 more
wiley   +1 more source

Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab

Therapeutic Advances in Musculoskeletal Disease
Background: The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported. Objective: To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with
Jan Brandt-Jürgens, Martin Rudwaleit, Frank Behrens, Christopher Ritchlin, Daniel Peterlik, Erhard Quebe-Fehling, Atul Deodhar   +6 more
doaj   +1 more source

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience

Dermatologica Sinica, 2017
Background/Objective: To date, no clinical trials have evaluated the therapeutic response among psoriasis patients switching from ustekinumab to secukinumab.
Ting-Shun Wang, Chih-Chieh Chan, Hsien-Yi Chiu, Tsen-Fang Tsai   +3 more
doaj   +1 more source

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. [PDF]

, 2019
Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of
Lee, Erica B, Liao, Wilson, Pithadia, Deeti J, Reynolds, Kelly A, Wu, Jashin J   +4 more
core